Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department

Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department

Jeanne Noble, Zlatan Coralic, Cortlyn Brown

As of March 30 th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine. 2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.

2020

DOI: 10.5811/westjem.2020.3.47328

Western Journal of Emergency Medicine

eScholarship Publishing, University of California

Medicine, Medical emergencies. Critical care. Intensive care. First aid